Intraoperative Methadone for Postoperative Pain Control
Randomized Control Study on the Effectiveness of Intraoperative Methadone on Postoperative Pain Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Singh Nair, MD
- Phone Number: 718.920.5932
- Email: sinair@montefiore.org
Study Contact Backup
- Name: Rie Seu, BA
- Phone Number: 8456645027
- Email: rie.seu@einsteinmed.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• All patients undergoing initial gastric sleeve resection
Exclusion Criteria:
- Age <18 years or >60 years
- Patients with BMI >60
- AHI > 30 (AHI = Apnea-Hypopnea Index), indicative of severe Obstructive Sleep Apnea (OSA)
- ASA IV or V (American Society of Anesthesiology physical status classification system)
- Patients taking opioids for chronic conditions in the last 10 days preceding the surgery
- Patients currently being treated for chronic opioid addiction
- Patients with severe psychiatric diagnoses
- Allergies to medications used in protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Methadone group
Patients in this group will receive intraoperative methadone.
|
One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo.
We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
|
|
No Intervention: Control group
Patients in this group will receive saline (placebo), instead of methadone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative opioid use
Time Frame: 24 hours postoperatively
|
Postoperative opioid use will be determined by the amount of morphine consumed (milligram morphine equivalents, MME) at 24 hours postoperatively
|
24 hours postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Postoperative opioid use
Time Frame: 48 hours postoperatively and approximately at 2 weeks (follow up visit upon discharge)
|
Total postoperative opioid use will be determined by the total amount of morphine consumed (milligram morphine equivalents, MME) at 48 hours postoperatively and during follow up visit
|
48 hours postoperatively and approximately at 2 weeks (follow up visit upon discharge)
|
|
Respiratory interventions
Time Frame: Up to 4 hours postoperatively
|
The number of respiratory interventions required postoperatively per patient in the PACU (Post-anesthesia care unit) will be determined
|
Up to 4 hours postoperatively
|
|
Duration of hospital stay
Time Frame: Approximately 5 days postoperatively
|
The average duration of hospitalization will be determined per patient
|
Approximately 5 days postoperatively
|
|
Patients Perception of Pain Management
Time Frame: 24 hours postoperatively
|
Patients perceptions of pain management will be measured by administration of the International Pain Outcomes (IPO) questionnaire on Post-Operative Day 1 (POD 1).
IPO will be used to assess key patient level outcomes of postoperative pain management and consists of 13 questions evaluating four outcome domains: 1) intensity of pain rated on Numeric Rating Scale (NRS) score (0 = no pain, 10 = worst possible pain); 2) interference of pain with activities and emotional well-being as determined by a score analogous to the NRS 0-10 scale above; 3) side effects of pain treatment, including nausea, drowsiness, itching, and dizziness, as determined by the NRS score >0; and 4) perception of care, treatment satisfaction and involvement in pain treatment decision-making on a scale from 0-10.
Scores are aggregated per patient with higher overall scores indicative of a worsening perception of pain management.
|
24 hours postoperatively
|
|
Patients Perception of Pain Management
Time Frame: 2 days postoperatively
|
Patients perceptions of pain management will be measured by administration of the International Pain Outcomes (IPO) questionnaire on POD 1 (Post-Operative Day 1).
IPO will be used to assess key patient level outcomes of postoperative pain management and consists of 13 questions evaluating four outcome domains: 1) intensity of pain rated on numeric rating score (0 = no pain, 10 = worst possible pain); 2) interference of pain with activities and emotional well-being as determined by a score analogous to the 0-10 scale above; 3) side effects of pain treatment, including nausea, drowsiness, itching, and dizziness, as determined by the NRS score >0; and 4) perception of care, treatment satisfaction and involvement in pain treatment decision-making on a scale from 0-10.
Scores are aggregated per patient with higher overall scores indicative of a worsening perception of pain management.
|
2 days postoperatively
|
|
Sedation Score (POSS)
Time Frame: 2 days postoperatively
|
Sedation score will be determined using the Pasero Opioid-induced Sedation Scale (POSS) in the Post-anesthesia Care Unit (PACU) and on the floor.
Average scores will be tabulated per patient using a four point numeric rating scale.
Scoring is as follows: 1 = Awake and alert; 2 = Slightly drowsy, easily aroused; 3 = Frequently drowsy, arousable, drifts off to sleep during conversation; 4 = Somnolent, minimal or no response to verbal and physical stimulation
|
2 days postoperatively
|
|
Agitation and Sedation Severity (RASS)
Time Frame: 2 days postoperatively
|
Agitation and Sedation severity will determined using the Richmond Agitation-Sedation Scale (RASS) in the PACU and on the floor.
Average scores will be determined per patient using a numeric rating scale ranging from +4 to -5 where +4 = combative, +3 = very agitated, +2 = agitated, +1 = restless, 0 = alert and calm, -1: = drowsy, -2 = light sedation, -3 = moderate sedation, -4 = deep sedation, and -5 = unarousable.
Ideal RASS scores range from -1 to 1.
|
2 days postoperatively
|
|
Opioid-related side effects
Time Frame: Up to 2 days postoperatively
|
Opioid related side effects including nausea, vomiting, pruritis, urinary retention, and necessity of supplemental oxygen will be recorded
|
Up to 2 days postoperatively
|
|
Early Mobilization
Time Frame: Up to 2 days postoperatively
|
The average duration of time to first ambulation after surgery will be recorded per patient
|
Up to 2 days postoperatively
|
|
GI recovery time
Time Frame: Up to 2 days postoperatively
|
The average duration of time to return of bowel function will be determined per patient
|
Up to 2 days postoperatively
|
|
Adverse events due to procedure or anesthesia
Time Frame: Up to 2 days postoperatively
|
Procedure related adverse events or adverse events related to anesthesia will be recorded
|
Up to 2 days postoperatively
|
|
Pain Scores
Time Frame: After 30 minutes in the PACU; upon discharge from PACU (variable timepoint); at 6, 12, 18, and 24 hours after being on the in-patient floor; and at hospital discharge
|
Pain scores will be assessed by a research assistant blinded to the study group at regular intervals.
Numerical pain scores (0=no pain, 10=most pain) will be assigned on an 11 point scale ranging from 0 (no pain) to 10 (most pain).
Since most patients who get bariatric surgery are discharged at POD 1, the research assistant will call the patient the morning of POD 2 to assess the pain score if not on the inpatient floor.
If the patients are not yet discharged, the pain score will be assessed the morning of POD 2, otherwise pain scores will be collected as detailed in the time frame below.
|
After 30 minutes in the PACU; upon discharge from PACU (variable timepoint); at 6, 12, 18, and 24 hours after being on the in-patient floor; and at hospital discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jennifer Choi, MD, Montefiore Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Respiratory System Agents
- Antitussive Agents
- Methadone
Other Study ID Numbers
Other Study ID Numbers
- 2022-14040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.